Previous 10 | Next 10 |
BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice Preside...
BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D....
BOSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors. Dr...
Atea Pharmaceuticals, Inc. (AVIR) Q1 2021 Earnings Conference Call May 13, 2021, 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President, Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman and CEO Janet Hammond - Chief Development Officer A...
Despite a ~54.0% loss in the year so far, Atea Pharmaceuticals ([[AVIR]] +23.3%) has climbed more than a fifth today after the company reported better than expected Q1 2021 financials yesterday.Atea in partnership with Roche recently initiated a late-stage study for an oral antiviral age...
Gainers: MoSys (MOSY) +43%.HyreCar (HYRE) +41%.Vivint Smart Home (VVNT) +26%.DoorDash (DASH) +26%.Intrusion (INTZ) +26%.One Stop Systems (OSS) +24%.LifeMD (LFMD) +24%.Atea Pharmaceuticals (AVIR) +24%.Cricut (CRCT) +23%.SemiLEDs (LEDS) +20%.Losers: CorMedix (CRMD) -25%...
The following slide deck was published by Atea Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Atea Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
Gainers: LifeMD (LFMD) +26%, Bionano Genomics (BNGO) +21%, Atea Pharmaceuticals (AVIR) +17%, DermTech (DMTK) +16%, Aesthetic Medical International (AIH) +12%.Losers: CorMedix (CRMD) -27%, Solid Biosciences (SLDB) -22%, PolarityTE (PT...
Atea Pharmaceuticals (AVIR): Q1 GAAP EPS of $0.34 beats by $0.39.Revenue of $66M beats by $34.39M.Cash and Cash Equivalents of $833.8M at March 31, 2021 compared to $850.1M at December 31, 2020.Press Release For further details see: Atea Pharmaceuticals EPS beats by $0.39, beats on...
Global Phase 3 MORNINGSKY trial of AT-527 in the outpatient setting recently initiated for the treatment of COVID-19 Enrollment advancing in Phase 1a trial of AT-752; drug candidate being developed for the treatment of dengue fever BOSTON, May 13, 2021 (GLOBE NEWSW...
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...